Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBT Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed EBT Margin for 5 consecutive years, with 83.03% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 2068.0% to 83.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 103.31%, a 9666.0% increase, with the full-year FY2025 number at 103.31%, up 9669.0% from a year prior.
  • EBT Margin was 83.03% for Q4 2025 at Rhythm Pharmaceuticals, up from 102.91% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 527.99% in Q4 2022 to a low of 97840.0% in Q1 2021.
  • A 5-year average of 6397.32% and a median of 218.97% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 9433326bps in 2022, then tumbled -69898bps in 2023.
  • Rhythm Pharmaceuticals' EBT Margin stood at 2798.84% in 2021, then skyrocketed by 119bps to 527.99% in 2022, then plummeted by -132bps to 170.99% in 2023, then soared by 39bps to 103.71% in 2024, then rose by 20bps to 83.03% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's EBT Margin are 83.03% (Q4 2025), 102.91% (Q3 2025), and 95.45% (Q2 2025).